Original title: Intraaortic Balloon Support for Myocardial Infarction with Cardiogenic Shock (for the IABP-Shock II Trial Investigator) Reference: Holger T, et al. NEJM 367;14:1287 The rate of mortality in cardiogenic shock secondary to acute myocardial infarction (AMI) is high even in patients receiving early revascularization. The use of an intra-aortic balloon counter-pulsation pump (IABP) according to the...
Original title: Walking Beyond the GRACE (Global Registry of Acute Coronary Events) Model in the Death Risk Stratification During Hospitalization in Patients With Acute Coronary Syndrome. Reference: Rapouseiras-Roubín S, et al. J Am Coll Cardiol Intv 2012;5:1117–25. Discriminatory power of risk score predictors become fundamental in the management of patients with acute coronary syndromes. This tool lets you...
It has been reported that the two stents technique is not superior to a provisional stent when treating bifurcations. However, the optimal approach to rescue a secondary branch (SB) when initially opting for provisional stenting has not been established. The aim of this study was to determine angioplasty indication using balloon or stent for...
Original title: The MASTER Trial – Prospective, Randomized, Multicenter Evaluation of a Polyethylene Terephthalate Micronet Mesh–Covered Stent (MGuard) in ST-Segment Elevation Myocardial Infarction. Reference: Gregg W. Stone et. al. J Am Coll Cardiol 2012; 60: 1975-1984 Primary angioplasty has proven effective in restoring epicardial flow but myocardial perfusion is often suboptimal. One of the main mechanisms is distal...
Original title: A Randomized Multicenter Study Comparing a Paclitaxel Drug-Eluting Balloon With a Paclitaxel-Eluting Stent in Small Coronary Vessels. The BELLO (Balloon Elution and Late Loss Optimization) Study Reference: Referencia: Azeem Latib et al J Am Coll Cardiol 2012;()doi:10.1016/j.jacc.2012.09.020 The utility of paclitaxel-eluting balloons to treat in-stent restenosis is known but data for novo lesions is more limited. ...
Original title: ISAR DESIRE 3: Drug-eluting balloon is best option for restenosis of limus-eluting stents Reference: Dr Robert Byrne. TCT 2012. Miami, Fl. The first of the ISAR DESIRE trials showed that drug-eluting stents (DES) were the best strategy for treating restenosis of a bare metal stent, the second ISAR DESIRE trial tested the hypothesis of changing or...
Original title: Strategies for Multivessel Revascularization in Patients with Diabetes. The FREEDOM Trial. Reference: Michael E. Farkouh et al. N Engl J Med 2012. DOI: 10.1056/NEJMoa1211585 This study was designed to determine the best revascularization strategy in diabetic patients with multivessel using current techniques of angioplasty (PCI) and surgery (CABG). Randomized 1:1 diabetic patients with injuries > 70%...
Original title: First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold A Multi-Imaging Modality Study. Reference: John Ormiston et al. Circ Cardiovasc Interv. 2012;5:620-632. The first bioabsorbable stents eluting everolimus showed a 6-month delayed recoil resulting in late lumen loss of 0.44 mm, (intermediate between a metal stent...
Reference: Fox y colaboradores. Short-term Outcomes of Acute Myocardial Infarction in Patients with Acute Kidney Injury: A Report from the National Cardiovascular Data Registry. Circulation 2012 (in press). The presence of chronic renal failure is common in patients referred for angioplasty. Its presence is associated with increased mortality and bleeding. However, the prevalence is unknown as...
Reference: Kandzari DE, Barrer CS, Leon MB, et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 2011; 4: 1119-28.2011; 4: 1119-28. Patients treated with zotarolimus-eluting stents (ZES) suffer no excess late ischemic events if they take dual antiplatelet therapy for 6 months instead of 12 months or longer,...